Advanz Pharma's bid to keep its Ocaliva treatment for rare liver disease primary biliary cholangitis (PBC) on the EU market has ended in failure. The European Commission revoked the conditional ...

MASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects between 6 million to 8 million people in the US alone and for some time has been billed as pharma's next big growth area.

After oral ingestion of pharmacological doses, the mean elimination half-life is 9–16 h, but this may be up to sevenfold longer in patients with liver cirrhosis.61 Concomitant administration of other ...